Trends in thyroid cancer incidence and mortality in the United States, 1974-2013

JAMA - Journal of the American Medical Association

Volumn 317, Issue 13, 2017, Pages 1338-1348

  Lim, Hyeyeun ^a   Devesa, Susan S ^a   Sosa, Julie A ^b   Check, David ^a   Kitahara, Cari M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; CANCER INCIDENCE; CANCER MORTALITY; CANCER REGISTRY; CANCER STAGING; CONTROLLED STUDY; DATA ANALYSIS; DEMOGRAPHY; DISEASE ASSOCIATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY RATE; OUTCOME ASSESSMENT; REVIEW; THYROID CANCER; TREND STUDY; UNITED STATES; ADOLESCENT; CARCINOMA; EPIDEMIOLOGY; INCIDENCE; MORTALITY; PATHOLOGY; THYROID NEOPLASMS; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; SEER PROGRAM; THYROID NEOPLASMS; UNITED STATES; YOUNG ADULT;

EID: 85017374424     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2017.2719     Document Type: Review

References (38)

1. Howlader N, Noone AM, Krapcho M, et al, eds. SEER Cancer Statistics Review, 1975-2013, National Cancer Institute. Bethesda, MD, based on November 2015 SEER data submission, posted to the SEER web site, April 2016. http://seer.cancer.gov/csr/1975-2013/Accessed March 13, 2017.
2. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA. 2006;295(18):2164-2167.
3. Kent WD, Hall SF, Isotalo PA, Houlden RL, George RL, Groome PA. Increased incidence of differentiated thyroid carcinoma and detection of subclinical disease. CMAJ. 2007;177(11):1357-1361.
4. Davies L, Welch HG. Current thyroid cancer trends in the United States. JAMA Otolaryngol Head Neck Surg. 2014;140(4):317-322.
5. Vaccarella S, Franceschi S, Bray F, Wild CP, Plummer M, Dal Maso L.Worldwide thyroid-cancer epidemic? N Engl J Med. 2016;375(7):614-617.
6. Enewold L, Zhu K, Ron E, et al. Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980-2005. Cancer Epidemiol Biomarkers Prev. 2009;18(3):784-791.
7. Kitahara CM, Sosa JA. The changing incidence of thyroid cancer. Nat Rev Endocrinol. 2016;12(11): 646-653.
8. National Cancer Institute, Surveillance, Epidemiology, and End Results Program. SEER∗Stat Database: Incidence-SEER 9 Regs Research Data, Nov 2015 Sub (1973-2013) -Linked To County Attributes-Total US, 1969-2014 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2016, based on the November 2015 submission. https://seer.cancer.gov/data/access.htmlAccessed March 13, 2017.
9. National Cancer Institute, Surveillance, Epidemiology, and End Results Program. SEER∗Stat Database: Mortality-All COD, Aggregated With State, Total US (1969-2013 , National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2016. Underlying mortality data provided by NCHS. https://seer.cancer.gov/data/access.html. Accessed March 13, 2017.
10. Chu KC, Miller BA, Feuer EJ, Hankey BF. Amethod for partitioning cancer mortality trends by factors associated with diagnosis. J Clin Epidemiol. 1994;47(12):1451-1461.
11. National Cancer Institute, Surveillance, Epidemiology, and End Results Program. SEER∗Stat Database: Incidence-Based Mortality-SEER 9 Regs Research Data, Nov 2015 Sub (1973-2013) -Linked To County Attributes-Total US, 1969-2014 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2016, based on the November 2015 submission. https://seer.cancer.gov/data/access.htmlAccessed March 13, 2017.
12. Forman D, Bray F, Brewster DH, et al, eds. Cancer Incidence in Five Continents, Vol 10 [electronic version]. Lyon, France: International Agency for Research on Cancer; 2013. http://ci5.iarc.fr Accessed March 13, 2017.
13. Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA, eds. SEER Summary Staging Manual-2000: Codes and Coding Instructions, National Cancer Institute, NIH Pub No. 01-4969, Bethesda, MD, 2001. https://seer.cancer.gov/tools/ssm/. Accessed March 13, 2017.
14. National Cancer Institute. Surveillance Epidemiology, and End Results Program website. Adjusted AJCC 6th ed T, N, M, and Stage. https://seer.cancer.gov/seerstat/variables/seer/ajcc-stage/6th/Accessed March 13, 2017.
15. Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26 (1):1-133.
16. National Cancer Institute. Surveillance Epidemiology, and End Results Program website. SEER∗Stat Software, latest release: version 8.3.2-April 14, 2016. https://seer.cancer.gov/seerstat/Accessed March 13, 2017.
17. Devesa SS, Donaldson J, Fears T. Graphical presentation of trends in rates. Am J Epidemiol. 1995;141(4):300-304.
18. National Cancer Institute. Surveillance Epidemiology, and End Results Program website. Joinpoint Trend Analysis Software. https://surveillance.cancer.gov/joinpoint/Accessed March 13, 2017.
19. Morris LG, Tuttle RM, Davies L. Changing trends in the incidence of thyroid cancer in the United States. JAMA Otolaryngol Head Neck Surg. 2016;142 (7):709-711.
20. Sosa JA, Hanna JW, Robinson KA, Lanman RB. Increases in thyroid nodule fine-needle aspirations, operations, and diagnoses of thyroid cancer in the United States. Surgery. 2013;154(6):1420-1426.
21. Mao Y, Xing M. Recent incidences and differential trends of thyroid cancer in the USA. Endocr Relat Cancer. 2016;23(4):313-322.
22. Kim BW, Yousman W, Wong WX, Cheng C, McAninch EA. Less is more: comparing the 2015 and 2009 American Thyroid Association Guidelines for Thyroid Nodules and Cancer. Thyroid. 2016;26 (6):759-764.
23. Dal Maso L, Bosetti C, La Vecchia C, Franceschi S. Risk factors for thyroid cancer. Cancer Causes Control. 2009;20(1):75-86.
24. Fazel R, Krumholz HM, Wang Y, et al. Exposure to low-dose ionizing radiation from medical imaging procedures. N Engl J Med. 2009;361(9):849-857.
25. Romei C, Fugazzola L, Puxeddu E, et al. Modifications in the papillary thyroid cancer gene profile over the last 15 years. J Clin Endocrinol Metab. 2012;97(9):E1758-E1765.
26. Mathur A, Moses W, Rahbari R, et al. Higher rate of BRAF mutation in papillary thyroid cancer over time. Cancer. 2011;117(19):4390-4395.
27. Jung CK, Little MP, Lubin JH, et al. The increase in thyroid cancer incidence during the last four decades is accompanied by a high frequency of BRAF mutations and a sharp increase in RAS mutations. J Clin Endocrinol Metab. 2014;99(2): E276-E285.
28. Kowalska A, Walczyk A, Kowalik A, et al. Increase in papillary thyroid cancer incidence is accompanied by changes in the frequency of the BRAF V600E mutation. Thyroid. 2016;26(4):543- 551.
29. Centers for Disease Control and Prevention. Prevalence of Overweight, Obesity, and Extreme Obesity Among Adults: United States, 1960-1962 Through 2011-2012. https://www.cdc.gov/nchs/data/hestat/obesity-Adult-11-12/obesity-Adult-11-12.htm. Accessed March 13, 2017.
30. Ng M, Freeman MK, Fleming TD, et al. Smoking prevalence and cigarette consumption in 187 countries, 1980-2012. JAMA. 2014;311(2):183-192.
31. Kitahara CM, McCullough ML, Franceschi S, et al. Anthropometric factors and thyroid cancer risk by histological subtype. Thyroid. 2016;26(2): 306-318.
32. Kitahara CM, Gamborg M, Berrington de González A, Sørensen TI, Baker JL. Childhood height and body mass index were associated with risk of adult thyroid cancer in a large cohort study. Cancer Res. 2014;74(1):235-242.
33. Kitahara CM, Linet MS, Beane Freeman LE, et al. Cigarette smoking, alcohol intake, and thyroid cancer risk. Cancer Causes Control. 2012;23(10):1615-1624.
34. Almquist M, Johansen D, Björge T, et al. Metabolic factors and risk of thyroid cancer in the Metabolic Syndrome and Cancer Project (Me-Can). Cancer Causes Control. 2011;22(5):743-751.
35. Wiersinga WM. Smoking and thyroid. Clin Endocrinol (Oxf). 2013;79(2):145-151.
36. Pellegriti G, Frasca F, Regalbuto C, Squatrito S, Vigneri R. Worldwide increasing incidence of thyroid cancer [published online May 7, 2013]. J Cancer Epidemiol. 2013;2013:965212. doi:10.1155/2013/965212.
37. Schlumberger M, Tahara M, Wirth LJ, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 2015;372(7):621-630.
38. Brose MS, Nutting CM, Jarzab B, et al; DECISION Investigators. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer. Lancet. 2014;384 (9940):319-328.